New study tracks how a common heart valve performs in people born with a bicuspid valve

NCT ID NCT03495050

Completed Knowledge-focused Sponsor: Clinique Pasteur Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 150 people with bicuspid aortic stenosis—a narrowed heart valve present from birth—who receive a transcatheter aortic valve replacement (TAVI) using the Evolut Pro or Evolut R XL device. Researchers will measure how well the valve works over time, including blood flow and any leakage. The goal is to see if this less-invasive procedure is safe and effective for this specific group of patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Evolut Pro/XL transcatheter aortic valve
What this could lead to: If successful, this study could confirm that the Evolut valve works well for people with bicuspid aortic stenosis, expanding treatment options for this common heart condition.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove the valve is better than alternatives. Results may not apply to all patients with bicuspid valves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BICUSPID AORTIC VALVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve disease 1 aortic valve disease 2 aortic valve stenosis Bicuspid Aortic Valve Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BICUSPID AORTIC VALVE

Contacts and locations

Locations

Clinique Pasteur

Toulouse, Occitanie, 31076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.